Fig. 3From: The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment Primary tumour location (a) and number of cases with ICI-related cardiovascular toxicity based on the immune checkpoint inhibitor used (b). GI: gastrointestinal. ICI: immune checkpoint inhibitorBack to article page